Recipharm Karlskoga, specialised in the manufacture of semi-solid products, and Pharmanest, a Stockholm-based pharmaceutical company specialising in developing products for local pain relief in obstetrics and gynaecology, have announced the formation of a new pharmaceutical manufacturing contract for SHACT.
Every year, millions of women around the world experience pain and discomfort during IUD insertion (intrauterine contraception). There are few treatment options with proven efficacy and safety available to these women. SHACT is a product based on an innovative formulation of lidocaine, a well-known anaesthetic, and a proprietary application device developed to simplify topical application in the cervix and uterus. SHACT has demonstrated convincing Phase II efficacy data as local anaesthesia in connection with IUD insertion and also recently reported positive data from a hysteroscopy study.
Recipharm and Pharmanest have reached a milestone in their existing collaboration and Pharmanest is now preparing its candidate SHACT for launch. Additionally, the companies have reached a long-term agreement for commercial manufacturing, with the precise product launch date to be announced later. Jointly, the two companies will offer commercial supply to any market that Pharmanest determine to enter for supply and sales of their first pharmaceutical product SHACT.
Ingela Palmkvist, general manager at Recipharm in Karlskoga, commented: “I really look forward to closely following the introduction of this product to various markets. Indeed, I believe it will make a highly significant difference to patients.”
Gunilla Lundmark, CEO at Pharmanest said: “I am very pleased that Pharmanest and Recipharm have entered into this new collaboration following the product development success achieved to date. Given the strong clinical data we are now rapidly moving toward commercialisation. We look forward to working closely with Recipharm for the commercial manufacture of the product and, indeed, to pooling our respective skills and capabilities to supply the pharmaceutical product to key target markets.”
